HS
HS
  • Home
  • Our team
  • OUR SERVICES
  • OUR RESEARCH
  • NEWS
  • Contact Us
  • Blog
  • More
    • Home
    • Our team
    • OUR SERVICES
    • OUR RESEARCH
    • NEWS
    • Contact Us
    • Blog
  • Home
  • Our team
  • OUR SERVICES
  • OUR RESEARCH
  • NEWS
  • Contact Us
  • Blog

OUR RESEARCH

 The research team, Washington Institute of Clinical Research, has consistently dedicated itself to clinical research, emphasizing areas such as autoimmune diseases, neurologic diseases, cancer, and rare diseases. We use advanced methods of big data analysis to drive forward our research endeavors and contribute to medical advancements. 

PUBLICATIONS

MemTrax memory test for Alzheimer’s Disease

 

  1. Liu W, Yu L, Deng Q, Li Y, Lu P, Yang J, Chen F, Li F, Zhou X, Bergeron MF, Ashford JW, Xu Q. Toward digitally screening and profiling AD: A GAMLSS approach of MemTrax in China. Alzheimers Dement. 2023 Aug 31. doi: 10.1002/alz.13430. Epub ahead of print. PMID: 37654085.
  2. Zhao X, Dai S, Zhang R, Chen X, Zhao M, Bergeron MF, Zhou X, Zhang J, Zhong L, Ashford JW, Liu X. Using MemTrax memory test to screen for post-stroke cognitive impairment after ischemic stroke: a cross-sectional study. Front Hum Neurosci. 2023 Jul 17;17:1195220. doi: 10.3389/fnhum.2023.1195220. PMID: 37529406; PMCID: PMC10387538.
  3. Chen W, Lin C, Su F, Fang Y, Liu G, Chen YC, Zhou X, Yao X, Ashford CB, Li F, Ashford JW, Fu QL, Pei Z. Early Diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease Using a Composite of MemTrax and Blood Biomarkers. J Alzheimers Dis. 2023;94(3):1093-1103. doi: 10.3233/JAD-230182. PMID: 37355900.
  4. Ashford JW, Schmitt FA, Bergeron MF, Bayley PJ, Clifford JO, Xu Q, Liu X, Zhou X, Kumar V, Buschke H, Dean M, Finkel SI, Hyer L, Perry G. Now is the Time to Improve Cognitive Screening and Assessment for Clinical and Research Advancement. J Alzheimers Dis. 2022;87(1):305-315. doi: 10.3233/JAD-220211. PMID: 35431257.
  5. Liu X, Chen X, Zhou X, Shang Y, Xu F, Zhang J, He J, Zhao F, Du B, Wang X, Zhang Q, Zhang W, Bergeron MF, Ding T, Ashford JW, Zhong L. Validity of the MemTrax Memory Test Compared to the Montreal Cognitive Assessment in the Detection of Mild Cognitive Impairment and Dementia due to Alzheimer's Disease in a Chinese Cohort. J Alzheimers Dis. 2021;80(3):1257-1267. doi: 10.3233/JAD-200936. PMID: 33646151.
  6. Bergeron MF, Landset S, Zhou X, Ding T, Khoshgoftaar TM, Zhao F, Du B, Chen X, Wang X, Zhong L, Liu X, Ashford JW. Utility of MemTrax and Machine Learning Modeling in Classification of Mild Cognitive Impairment. J Alzheimers Dis. 2020;77(4):1545-1558. doi: 10.3233/JAD-191340. PMID: 32894241; PMCID: PMC7683062.
  7. Zhou X, Ashford JW. Advances in screening instruments for Alzheimer's disease. Aging Med (Milton). 2019 May 31;2(2):88-93. doi: 10.1002/agm2.12069. PMID: 31942517; PMCID: PMC6880670.

Autoimmune Disease

 

  1. Li HY, Xia M, Song M, Xie Y, Wang Q, Yue YX, Li HF. Rs1800629 polymorphism in TNF-alpha is associated with the susceptibility and initial short-term glucocorticoids efficacy in myasthenia gravis patients. J Neuroimmunol. 2024 Feb 15;387:578269. doi: 10.1016/j.jneuroim.2023.578269. 
  2. Li HY, Jiang P, Xie Y, Liang B, Li L, Zhao C, Yue YX, Li HF. Criteria for Treatment Response in Myasthenia Gravis: Comparison Between Absolute Change and Improvement Percentage in Severity Scores. Front Neurol. 2022 Jun 2;13:880040. doi: 10.3389/fneur.2022.880040. PMID: 35720071; PMCID: PMC9201395.
  3. Han JL, Yue YX, Gao X, Xie YC, Hao HJ, Li HY, Yu XL, Li J, Duan RS, Li HF. Vitamin D Receptor Polymorphism and Myasthenia Gravis in Chinese Han Population. Front Neurol. 2021 Feb 9;12:604052. doi: 10.3389/fneur.2021.604052. PMID: 33633666; PMCID: PMC7900549.
  4. Yue YX, Gao X, Tang TP, Xie Y, Gu CK, Hao HJ, Li HY, Ding XJ, Song M, Guo SG, Li HF. Complement C3 polymorphism is associated with the susceptibility of myasthenia gravis in Chinese adult patients. J Neuroimmunol. 2021 Apr 15;353:577487. doi: 10.1016/j.jneuroim.2021.577487. Epub 2021 Jan 30. PMID: 33578311.
  5. Cai GM, Gao Z, Yue YX, Xie YC, Gao X, Hao HJ, Zhang XJ, Wang Q, Liang B, Li HF. Association between CTLA-4 gene polymorphism and myasthenia gravis in a Chinese cohort. J Clin Neurosci. 2019 Nov;69:31-37. doi: 10.1016/j.jocn.2019.08.079. Epub 2019 Aug 28. PMID: 31473094.
  6. Jiang P, Yue YX, Hong Y, Xie Y, Gao X, Gu CK, Hao HJ, Qin Y, Ding XJ, Song M, Li HF, Zhang X. IL-4Rα Polymorphism Is Associated With Myasthenia Gravis in Chinese Han Population. Front Neurol. 2018 Jul 10;9:529. doi: 10.3389/fneur.2018.00529. PMID: 30042722; PMCID: PMC6048264.

Medical Bibliometrics and Big Data Analysis

  1. Wen Q, Cao L, Yang C, Xie Y. The Electrophysiological Features in X-Linked Charcot-Marie-Tooth Disease With Transient Central Nervous System Deficits. Front Neurol. 2018 Jun 27;9:461. doi: 10.3389/fneur.2018.00461. PMID: 30013503; PMCID: PMC6036262. 

cANCER rESEARCH

  1. Cao Y, He M, Liu Z, Chen K, Denis K 1st, Zhang J, Zou J, Semchenko BS, Efetov SK. Evaluation of the efficacy of natural orifice specimen extraction surgery versus conventional laparoscopic surgery for colorectal cancers: A systematic review and meta-analysis. Colorectal Dis. 2025 Jan;27(1):e17279. doi: 10.1111/codi.17279. PMID: 39763245.
  2. Bai J, Wang Z, Yang M, Xiang J, Liu Z. Disrupting CENP-N mediated SEPT9 methylation as a strategy to inhibit aerobic glycolysis and liver metastasis in colorectal cancer. Clin Exp Metastasis. 2024 Dec;41(6):971-988. doi: 10.1007/s10585-024-10316-z. 
  3.  Yang YX, Tang Y, Li N, Tang Y, Cheng YJ, Yang L, Fang H, Lu NN, Qi SN, Chen B, Wang SL, Song YW, Liu YP, Li YX, Liu Z, Liang JW, Zhang HZ, Zhou HT, Wang J, Liu WY, Jin J. Comprehensive geriatric assessment guided radiotherapy in elderly patients with locally advanced rectal cancer-exploratory results on nonoperative cohort of a multicenter prospective study. Ther Adv Med Oncol. 2024 Nov 19;16:17588359241296386. doi: 10.1177/17588359241296386. PMID: 39563720; PMCID: PMC11574900.
  4.  Cao Y, He M, Chen K, Liu Z, Khlusov DI, Khorobrykh TV, Cao X, Panova PD, Efetov SK, Kazaryan AM. Short- and long-term outcomes after surgical treatment of 5918 patients with splenic flexure colon cancer by extended right colectomy, segmental colectomy and left colectomy: a systematic review and meta-analysis. Front Oncol. 2024 Apr 15;14:1244693. doi: 10.3389/fonc.2024.1244693. PMID: 38686198; PMCID: PMC11057231.

DR. Ryan Reyes' pUBLICATIONS

  1. Bai H, Padron AS, Deng Y, Liao YJ, Murray CJ, Ontiveros C, Kari SJ, Kancharla A, Kornepati AVR, Garcia M, Reyes RM, Gupta HB, Conejo-Garcia JR, Curiel T. Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects. J Immunother Cancer. 2023 Feb;11(2):e004871. doi: 10.1136/jitc-2022-004871. PMID: 36759012; PMCID: PMC9923271.
  2. Garcia MG, Deng Y, Murray C, Reyes RM, Padron A, Bai H, Kancharla A, Gupta H, Shen-Orr S, Curiel TJ. Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice. Aging Cancer. 2022 Mar;3(1):68-83. doi: 10.1002/aac2.12045. Epub 2022 Feb 25. PMID: 36876140; PMCID: PMC9980712.
  3. Reyes RM, Zhang C, Deng Y, Ji N, Mukherjee N, Padron AS, Clark CA, Svatek RS, Curiel TJ. CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation. Oncoimmunology. 2021 Nov 22;10(1):2006529. doi: 10.1080/2162402X.2021.2006529. PMID: 34858732; PMCID: PMC8632314.
  4. Deng Y, Reyes RM, Zhang C, Conejo-Garcia J, Curiel TJ. Targeting Ovarian Cancer with IL-2 Cytokine/Antibody Complexes: A Summary and Recent Advances. J Cell Immunol. 2021;3(6):387-396. doi: 10.33696/immunology.3.122. PMID: 36968176; PMCID: PMC10035448.
  5. Zhang D, Reyes RM, Osta E, Kari S, Gupta HB, Padron AS, Kornepati AVR, Kancharla A, Sun X, Deng Y, Wu B, Vadlamudi R, Li R, Svatek RS, Curiel TJ. Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy. Cancer Med. 2021 Mar;10(6):2137-2152. doi: 10.1002/cam4.3739. Epub 2021 Feb 24. PMID: 33626233; PMCID: PMC7957205.
  6. Ji N, Mukherjee N, Reyes RM, Gelfond J, Javors M, Meeks JJ, McConkey DJ, Shu ZJ, Ramamurthy C, Dennett R, Curiel TJ, Svatek RS. Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study. J Immunother Cancer. 2021 Mar;9(3):e001941. doi: 10.1136/jitc-2020-001941. PMID: 33653802; PMCID: PMC7929866.
  7. Reyes RM, Deng Y, Zhang D, Ji N, Mukherjee N, Wheeler K, Gupta HB, Padron AS, Kancharla A, Zhang C, Garcia M, Kornepati AVR, Boyman O, Conejo-Garcia JR, Svatek RS, Curiel TJ. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation. J Immunother Cancer. 2021 Apr;9(4):e002051. doi: 10.1136/jitc-2020-002051. PMID: 33849925; PMCID: PMC8051418.
  8. Ji N, Mukherjee N, Shu ZJ, Reyes RM, Meeks JJ, McConkey DJ, Gelfond JA, Curiel TJ, Svatek RS. γδ T Cells Support Antigen-Specific αβ T cell-Mediated Antitumor Responses during BCG Treatment for Bladder Cancer. Cancer Immunol Res. 2021 Dec;9(12):1491-1503. doi: 10.1158/2326-6066.CIR-21-0285. Epub 2021 Oct 4. PMID: 34607803; PMCID: PMC8691423.
  9. Reyes RM, Rios E, Barney S, Hugen CM, Michalek JE, Lotan Y, Messing EM, Svatek RS. A Randomized Feasibility Trial Comparing Surveillance Regimens for Patients with Low and Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2021;7(3):285-295. doi: 10.3233/blc-201535. PMID: 34621937; PMCID: PMC8494135.
  10. Drerup JM, Deng Y, Pandeswara SL, Padrón ÁS, Reyes RM, Zhang X, Mendez J, Liu A, Clark CA, Chen W, Conejo-Garcia JR, Hurez V, Gupta H, Curiel TJ. CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade. Cancer Res. 2020 Nov 15;80(22):5063-5075. doi: 10.1158/0008-5472.CAN-20-0002. Epub 2020 Sep 18. PMID: 32948605; PMCID: PMC7669742.
  11. Rios EM, Parma MA, Fernandez RA, Clinton TN, Reyes RM, Kaushik D, Pruthi D, Mansour AM, Mukherjee N, Gelfond J, Wheeler KM, Svatek RS. Urinary Diversion Disparity Following Radical Cystectomy for Bladder Cancer in the Hispanic Population. Urology. 2020 Mar;137:66-71. doi: 10.1016/j.urology.2019.12.017. Epub 2019 Dec 27. PMID: 31883879; PMCID: PMC7063861.

Copyright © 2016 Healsan - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept